RNAAtrium Therapeutics, Inc.
Next earnings ≈ Aug 13, 2026 · est. from filing cadence
Last earnings -0.2% on 2026-05-14
$12.46
▼ -3.49%$12.46▼ -15.53%
over 1Y
L $11.55H $16.54
Our buy Our hold Our sell Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today
-3.5%
1W
-4.2%
1M
+6.8%
3M
-2.0%
YTD
-15.5%
1Y
-15.5%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 5 analysts
Buy
Mixed signals in the latest filings.
This call stands until the filings change it — the engine re-rates on new 10-K/10-Q/8-K facts, never on price moves. Hit Watch above to follow RNA (Pro alerts fire the moment a rating flips), or catch every change in Saturday’s Flip Side. How to read a call
Atrium Therapeutics, Inc. shows limited reported revenue.
On these fundamentals, RNA screens as SELL on the SEC figures.
Is RNA a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread~60d expiry
- Long put 12.5 @ ~0.82 est
- Short put 11 @ ~0.25 est
debit $57max +$93max −$57BE 11.93
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Key statistics
Valuation
Enterprise value$221M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timelineSEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗SCHEDULE 13GFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-142026-05-14open ↗SCHEDULE 13GFiling2026-04-27open ↗4Period ending 2026-04-202026-04-22open ↗4Period ending 2026-04-202026-04-22open ↗4Period ending 2026-04-202026-04-22open ↗4Period ending 2026-04-202026-04-22open ↗4Period ending 2026-04-202026-04-22open ↗4Period ending 2026-04-202026-04-22open ↗S-8Filing2026-04-17open ↗SCHEDULE 13GFiling2026-04-08open ↗
Frequently asked
- Is Atrium Therapeutics, Inc. (RNA) a buy?
- RNA currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
New filings change verdicts
The daily Brief delivers our freshest calls, rating flips and the filings behind them — every morning, free.
Sources: SEC EDGAR (CIK 0002093101, latest 10-Q filed 2026-05-14) · EODHD · as of 7/12/2026, 12:12:28 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 12, 2026, 8:12 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.